Ductal adenocarcinoma of the prostate is a rare histological variant that only represents < 1% of prostate tumors.
This histological variant has several important clinical implications with respect to their evolution, clinical prognosis, and treatment. We report the case of a 64-year-old patient with ductal adenocarcinoma of the prostate, which progresses to castration-resistant prostate cancer, that was treated with abiraterone acetate with good clinical response, to our knowledge, the first case of ductal adenocarcinoma of the prostate in treatment with abiraterone acetate.
Written by:
Linden-Castro E, Pelayo-Nieto M, Alias-Melgar A, Espinosa-Perezgrovas D, Ramirez-Galindo I, Catalan-Quinto G. Are you the author?
Urology Department, Centro Medico Nacional 20 de Noviembre, Félix Cuevas 540, Del Valle, Benito Juárez, 03229 Ciudad de México, DF, Mexico.
Reference: Case Rep Urol. 2014;2014:508305.
doi: 10.1155/2014/508305
PubMed Abstract
PMID: 24891969
UroToday.com Prostate Cancer Section
